GlassScriptPhysician profile
Carlos A Silva
NPI 1457451437
$244,586.92
in general payments reported to CMS, 2019-2025
45 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $26K · 2021: $43K · 2022: $40K · 2023: $22K · 2024: $23K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $15K · Honoraria: $2,250 · Travel and Lodging: $1,714 · Education: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,030.00 |
| Food and Beverage | $15,360.35 |
| Honoraria | $2,250.00 |
| Travel and Lodging | $1,714.23 |
| Education | $716.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $63,886.22 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $63,647.20 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Mallinckrodt Hospital Products INC. | $45,249.85 | 2020-2025 | Acthar |
| Insmed, INC. | $29,707.21 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Enterprises LLC | $8,820.47 | 2019 | |
| Amgen INC. | $7,040.96 | 2021-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $5,037.63 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $3,205.90 | 2022-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $3,009.18 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,051.42 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| United Therapeutics Corporation | $1,702.68 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $1,341.49 | 2019-2025 | |
| Genentech USA, INC. | $1,199.18 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $1,182.80 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $1,063.53 | 2019-2025 | Prolastin-C Liquid, Xembify |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $767.58 | 2021-2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $697.04 | 2020-2025 | Glassia |
| Mylan Specialty L.P. | $641.21 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $591.22 | 2021-2025 | Winrevair |
| Philips North America LLC | $524.27 | 2019-2025 | Vest Therapy Und |
| Electromed, INC. | $363.23 | 2019-2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $327.96 | 2019-2022 | |
| Gilead Sciences, INC. | $259.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $238.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $221.97 | 2022-2025 | |
| Viatris Specialty LLC | $217.29 | 2025 | Yupelri |
| Pharming Healthcare, INC. | $186.33 | 2022-2024 | Joenja, Ruconest |
| Baxter Healthcare | $168.57 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Kaleo, INC. | $165.05 | 2019-2020 | |
| Inogen, INC. | $140.64 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pfizer INC. | $133.83 | 2020-2024 | |
| Pulmonx Corporation | $132.48 | 2021-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Alexion Pharmaceuticals, INC. | $97.34 | 2022-2024 | Ultomiris |
| Advanced Respiratory, INC | $95.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $89.94 | 2019-2023 | |
| Resmed Corp | $87.18 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $66.23 | 2025 | Alvesco |
| Circassia INC. | $45.74 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $44.91 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $42.43 | 2019-2021 | |
| Optinose US, INC. | $34.70 | 2019 | |
| Csl Behring | $19.24 | 2020 | |
| Verona Pharma, INC. | $16.63 | 2025 | Ohtuvayre |
| Phadia US INC. | $13.69 | 2022 | |
| Esperion Therapeutics, INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.